Pharmacokinetic features
The pharmacokinetics of Leflunomidum is based on the prodrug concept. Upon administration, the initial molecule is pharmacologically inactive. To exhibit therapeutic activity, the drug must undergo mandatory metabolic transformations.
The liver is the primary organ responsible for this transformation. Chemical modification of the drug structure occurs within the hepatic tissue, yielding the active metabolite. This metabolite subsequently enters the systemic circulation and interacts with cellular targets to produce all claimed clinical effects.
Mechanism of action at the cellular level
The mechanism of action of the active metabolite unfolds at the biochemical level and involves strictly specific enzymatic inhibition. The process can be divided into several consecutive stages:
- Enzyme blockade. The main target of the drug is the enzyme dihydroorotate dehydrogenase. The drug acts as its potent inhibitor.
- Cessation of pyrimidine synthesis. Inhibition of this enzyme leads to the cessation of pyrimidine production within the cell.
- Blockade of cell division. Since pyrimidines are critically necessary for normal cell division, their deficiency makes this process impossible.
- Suppression of lymphocyte proliferation. The lack of pyrimidines primarily affects the cells of the immune system. The drug causes pronounced suppression of lymphocyte proliferation (reproduction), thereby interrupting the pathological immune response.
Pharmacodynamics and clinical application
Pharmacodynamic effects logically stem from the mechanism of action. By suppressing excessive lymphocyte activity, the drug exerts a complex effect on the body:
- Anti-inflammatory effect: a decrease in the pool of active immune cells naturally reduces the severity of the inflammatory process.
- Analgesic effect: alleviation of inflammation leads to a secondary reduction in the patient's pain syndrome.
- Slowing of joint destruction: the drug can protect joint surfaces from destruction. This structure-modifying effect is achieved by inhibiting osteoclast activity.
In clinical practice, this agent is used quite flexibly. It can be prescribed by a physician either as monotherapy or as combination therapy—for example, coupled with methotrexate to achieve a more pronounced therapeutic response.
Adverse reactions and contraindications
Therapy is associated with the risk of developing several side effects affecting various organ systems. They can be divided into the following groups:
- Gastrointestinal tract (GIT): patients frequently encounter dyspeptic disorders, among which nausea and diarrhea are most characteristic.
- General disorders: systemic drug effects may manifest as headache, unexplained weight loss, and alopecia.
- Immune system: the risk of allergic reactions of varying severity persists.
The absolute and strictest contraindication to prescription is pregnancy. The drug has a proven teratogenic effect, meaning it is capable of disrupting embryonic development; therefore, its use in pregnant women is strictly prohibited.
Briefly: answers to topical questions
In which specific diseases is the prescription of leflunomide indicated?
The prescription of leflunomide is indicated for the treatment of rheumatoid and psoriatic arthritis.
- Rheumatoid arthritis — used as a primary disease-modifying antirheumatic drug as monotherapy or in combination with methotrexate.
- Psoriatic arthritis — used as an immunosuppressant as part of basic anti-inflammatory therapy in adult patients and children.
To remember the core concept, use the phrase: "Leflunomide Limits Lymphocyte Pyrimidines via the Piver [Liver]." The letter "L" reminds of the connection with lymphocytes, and "P" of the liver's role in prodrug activation and blockade of pyrimidine synthesis.
Class and exam questions
Why is leflunomide called a prodrug?
Because it is inactive in its original form. It acquires pharmacological activity only after metabolic transformation in the liver, where it turns into the active metabolite.
Which enzyme does the drug block?
The main target is the enzyme dihydroorotate dehydrogenase. Its inhibition leads to the cessation of pyrimidine synthesis necessary for cell division.
How is joint destruction slowed down?
The drug suppresses osteoclast activity. This slows down the destruction of joint surfaces during inflammatory processes.
Can the drug be prescribed to pregnant women?
Categorically no. It has a proven teratogenic effect and is strictly contraindicated during pregnancy.
What else to study on this topic
- Biochemical cascade of pyrimidine synthesis and the role of dihydroorotate dehydrogenase
- Mechanisms of prodrug activation in hepatic tissues
- Interaction of leflunomide and methotrexate in combination therapy
- Pathogenesis of osteoclast suppression by disease-modifying antirheumatic drugs
- Teratogenic effects of pharmacological drugs: mechanisms and consequences
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Leflunomide" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the "Analgesics" section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.